Cargando…
MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice
Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberc...
Autores principales: | Aguilo, Nacho, Uranga, Santiago, Marinova, Dessislava, Monzon, Marta, Badiola, Juan, Martin, Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Churchill Livingstone
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727503/ https://www.ncbi.nlm.nih.gov/pubmed/26786657 http://dx.doi.org/10.1016/j.tube.2015.10.010 |
Ejemplares similares
-
MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic
por: Gonzalo-Asensio, Jesus, et al.
Publicado: (2017) -
MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice
por: Broset, Esther, et al.
Publicado: (2019) -
Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo
por: Uranga, Santiago, et al.
Publicado: (2016) -
New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia
por: Tarancón, Raquel, et al.
Publicado: (2020) -
Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection
por: Dijkman, Karin, et al.
Publicado: (2021)